Discover more insights into Cytogenetic Risk

Keywords frequently search together with Cytogenetic Risk

Narrow sentence examples with built-in keyword filters

Cytogenetic Risk sentence examples within Intermediate Cytogenetic Risk



Gene expression profiling in normal cytogenetic acute myeloid leukaemia of Malay patient



Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)


Cytogenetic Risk sentence examples within Adverse Cytogenetic Risk



Dysregulation of CCAAT/enhancer binding protein-alpha (CEBPA) expression in the bone marrow of acute myeloid leukemia patients



Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.


Cytogenetic Risk sentence examples within Poor Cytogenetic Risk



Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A singlecenter study.



Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients




Cytogenetic Risk sentence examples within High Cytogenetic Risk



Targeting UCHL1 Induces Cell Cycle Arrest in High-Risk Multiple Myeloma with t(4;14)



Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma


Cytogenetic Risk sentence examples within Assign Cytogenetic Risk



Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission



Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330


Cytogenetic Risk sentence examples within Standard Cytogenetic Risk



Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey



Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial


Cytogenetic Risk sentence examples within cytogenetic risk group



Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial



Disseminated intravascular coagulopathy in non-promyelocytic acute myeloid leukemia: Incidence, clinical and laboratory features and prognostic significance


Cytogenetic Risk sentence examples within cytogenetic risk category



Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes



A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study.


Cytogenetic Risk sentence examples within cytogenetic risk stratification



MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia.



Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome


Cytogenetic Risk sentence examples within cytogenetic risk classification



Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT



Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.


Cytogenetic Risk sentence examples within cytogenetic risk statu



De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases



Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma


Cytogenetic Risk sentence examples within cytogenetic risk factor



Autologous and Allogeneic Hematopoietic Cell Transplantation for Diffuse Large B-cell Lymphoma-Type Richter Syndrome.



Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia


Cytogenetic Risk sentence examples within cytogenetic risk profile



Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer.



The VR-DCEP regimen rescues mobilization failures and controls refractory disease in multiple myeloma


Cytogenetic Risk sentence examples within cytogenetic risk patient



CKS1-dependent proteostatic regulation has dual roles combating acute myeloid leukemia whilst protecting normal hematopoiesis



Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A singlecenter study.


More Cytogenetic Risk sentence examples
10.1007/s00277-021-04465-4

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial


More Cytogenetic Risk sentence examples
10.1186/s43042-021-00154-z

Dysregulation of CCAAT/enhancer binding protein-alpha (CEBPA) expression in the bone marrow of acute myeloid leukemia patients


More Cytogenetic Risk sentence examples
10.1038/s41375-021-01433-9

Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma


More Cytogenetic Risk sentence examples
10.1182/blood.2021011103

Genetic Identification of AML Patients Older than 60 years Achieving Long-term Survival with Intensive Chemotherapy.



Disseminated intravascular coagulopathy in non-promyelocytic acute myeloid leukemia: Incidence, clinical and laboratory features and prognostic significance


More Cytogenetic Risk sentence examples
10.1667/RADE-21-00116.1

Alpha-Particle Exposure Induces Mainly Unstable Complex Chromosome Aberrations which do not Contribute to Radiation-Associated Cytogenetic Risk.


More Cytogenetic Risk sentence examples
10.3329/BJMS.V20I3.52798

Gene expression profiling in normal cytogenetic acute myeloid leukaemia of Malay patient


More Cytogenetic Risk sentence examples
10.26442/00403660.2021.04.200682

Analysis of the effectiveness of multiple myeloma treatment based on the clinical experience of European countries


More Cytogenetic Risk sentence examples
10.1101/2020.12.27.423419

CKS1-dependent proteostatic regulation has dual roles combating acute myeloid leukemia whilst protecting normal hematopoiesis



Splenectomy for haemophagocytic lymphohistiocytosis of unknown origin: risks and benefits in 21 patients


More Cytogenetic Risk sentence examples
10.1038/s41598-021-84190-0

Development of a poor-prognostic-mutations derived immune prognostic model for acute myeloid leukemia



Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A singlecenter study.


More Cytogenetic Risk sentence examples
10.1016/j.clml.2021.02.001

The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center.


More Cytogenetic Risk sentence examples
10.1200/JCO.2021.39.15_SUPPL.E19002

MRD assessment using NGS in patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation: Meta-analysis.


More Cytogenetic Risk sentence examples
10.1016/S2152-2650(21)01970-4

MM-315: Impact of Stratification of Levels of Serum Lactate Dehydrogenase (LDH) at Diagnosis on Overall Survival (OS) in Newly Diagnosed Multiple Myeloma (NDMM)


More Cytogenetic Risk sentence examples
10.1038/s41375-021-01131-6

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)


More Cytogenetic Risk sentence examples
10.11406/rinketsu.62.289

[Allogeneic transplantation for myelodysplastic syndromes: analyses of the Japanese registry data].


More Cytogenetic Risk sentence examples
10.1182/bloodadvances.2021004865

Autologous and Allogeneic Hematopoietic Cell Transplantation for Diffuse Large B-cell Lymphoma-Type Richter Syndrome.


More Cytogenetic Risk sentence examples
10.3389/fonc.2021.744009

Editorial: Special Issue on Innovative Multi-Disciplinary Approaches for Precision Studies in Leukemia


More Cytogenetic Risk sentence examples
10.1038/s41409-021-01324-8

Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients



Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT


More Cytogenetic Risk sentence examples
10.1016/j.leukres.2021.106584

MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia.


More Cytogenetic Risk sentence examples
10.3389/fonc.2021.624405

Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey


More Cytogenetic Risk sentence examples
10.1007/s10552-021-01422-4

Impact of race on outcomes in intermediate-risk acute myeloid leukemia.


More Cytogenetic Risk sentence examples
10.1016/S2152-2650(21)01986-8

MM-429: Impact of Prolonged Lenalidomide Maintenance (≥3 years) and Outcomes in Patients with Multiple Myeloma Post-Autologous Stem Cell Transplant



De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases


More Cytogenetic Risk sentence examples
10.1016/j.clml.2021.01.011

Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia.


More Cytogenetic Risk sentence examples
10.3390/cancers13102458

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial


More Cytogenetic Risk sentence examples
10.1016/j.hemonc.2021.08.001

High expression of long noncoding RNA NORAD is associated with poor clinical outcomes in non-M3 acute myeloid leukemia patients.



Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics


More Cytogenetic Risk sentence examples
10.1136/EJHPHARM-2021-EAHPCONF.119

4CPS-287 Impact of SARS-CoV-2 infection in acute myeloid leukaemia patients: experience of the Pethema registry


More Cytogenetic Risk sentence examples
10.1016/S2152-2650(21)01684-0

AML-162: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study


More Cytogenetic Risk sentence examples
10.1182/blood.2021011103

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.


More Cytogenetic Risk sentence examples
10.1200/JCO.2021.39.15_SUPPL.E20016

Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).


More Cytogenetic Risk sentence examples
10.1182/blood.2020008812

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.


More Cytogenetic Risk sentence examples
10.1200/JCO.2021.39.15_SUPPL.TPS8054

Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study.


More Cytogenetic Risk sentence examples
10.3390/cancers13051083

Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation



Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk



TERT rs2853669 as predictor for overall survival in patients with acute myeloid leukemia


More Cytogenetic Risk sentence examples
10.3389/pore.2021.606567

Targeting UCHL1 Induces Cell Cycle Arrest in High-Risk Multiple Myeloma with t(4;14)


More Cytogenetic Risk sentence examples
10.1038/s41409-021-01334-6

The EBMT Cytogenetic Risk Score maintains its prognostic significance in acute myeloid leukemia following allogeneic stem cell transplantation in a cohort with 40% of patients transplanted with in vitro partial T-cell depleted graft


More Cytogenetic Risk sentence examples
10.1186/s13045-021-01086-2

Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia


More Cytogenetic Risk sentence examples
10.1016/j.clml.2021.07.027

On Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated With Allogeneic Stem-Cell Transplantation.


More Cytogenetic Risk sentence examples
10.3389/fonc.2021.700234

The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation


More Cytogenetic Risk sentence examples
10.1200/JCO.2021.39.15_SUPPL.7014

Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).


More Cytogenetic Risk sentence examples
10.1038/s41408-021-00492-6

Real-world renal function among patients with multiple myeloma in the United States


More Cytogenetic Risk sentence examples
10.1182/bloodadvances.2021004462

Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning.


More Cytogenetic Risk sentence examples
10.1016/j.mayocp.2020.06.060

Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.


More Cytogenetic Risk sentence examples
10.3389/fonc.2021.732088

Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT


More Cytogenetic Risk sentence examples
10.1016/S2152-2650(21)01987-X

MM-431: A Comparison Between Daratumumab and Non-Daratumumab-Based Salvage Regimens Used at First Relapse Post-Lenalidomide Maintenance in Multiple Myeloma



C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study


More Cytogenetic Risk sentence examples
10.1007/s00277-021-04529-5

Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma


More Cytogenetic Risk sentence examples
10.1016/j.bbmt.2019.11.021

Post remission consolidation by autologous HCT for AML in CR1, negative implications for subsequent allogeneic HCT in CR2. A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).


More Cytogenetic Risk sentence examples
10.1182/bloodadvances.2018025718

Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL.



Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.


More Cytogenetic Risk sentence examples
10.3324/haematol.2018.212217

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes


More Cytogenetic Risk sentence examples
10.1016/J.BBMT.2018.12.392

Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study


More Cytogenetic Risk sentence examples
10.21320/2500-2139-2019-12-2-145-153

Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial


More Cytogenetic Risk sentence examples
10.1186/s40164-019-0127-z

Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia


More Cytogenetic Risk sentence examples
10.1080/17512433.2019.1573668

Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review


More Cytogenetic Risk sentence examples
10.1016/j.leukres.2019.05.010

Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer.


More Cytogenetic Risk sentence examples
10.1038/s41375-019-0517-6

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma



Real‐world experience with decitabine as a first‐line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy


More Cytogenetic Risk sentence examples
10.1016/J.CLML.2019.05.002

Outcomes of Autologous Hematopoietic Cell Transplantation Compared With Chemotherapy Consolidation Alone for Non-High-Risk Acute Myeloid Leukemia in First Complete Remission in a Minority-Rich Inner-City Cohort With Limited Access to Allografts.


More Cytogenetic Risk sentence examples
10.1016/J.BBMT.2018.12.806

Do Cytogenetics Predict Likelihood to Attain Minimal Residual Disease (MRD) Post Autologous Stem Cell Transplantation (SCT) in Multiple Myeloma (MM)


More Cytogenetic Risk sentence examples
10.1080/14737140.2019.1674142

The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma


More Cytogenetic Risk sentence examples
10.1080/10428194.2018.1493729

Is fluorescence in-situ hybridization sufficient in patients with myelodysplastic syndromes and insufficient cytogenetic testing?


More Cytogenetic Risk sentence examples
10.1038/s41409-019-0735-6

The VR-DCEP regimen rescues mobilization failures and controls refractory disease in multiple myeloma


More Cytogenetic Risk sentence examples
10.1182/bloodadvances.2018030726

A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study.


More Cytogenetic Risk sentence examples
10.11406/rinketsu.60.1411

[Clinical characteristics of young multiple myeloma patients: a single-center analysis of 30 patients].


More Cytogenetic Risk sentence examples
10.3390/cancers11121958

Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia


More Cytogenetic Risk sentence examples
10.1007/s00277-019-03600-6

Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients—a real-world experience from India



Cytogenetic Risk
Encyclopedia